GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$1.92+0.05 (+2.95%)
Close on Nov 16, 2026Market cap $86.87MP/E –Yield –
Genelux EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Genelux's EPS for the twelve months ending Jun 30, 2026 was -$0.86. For fiscal 2025 it was -$0.86.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.86 | – |
| FY2024 | Dec 31, 2024 | -$0.95 | – |
| FY2023 | Dec 31, 2023 | -$1.16 | – |
| FY2022 | Dec 31, 2022 | -$0.57 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.21 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.20 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.24 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.21 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.20 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.21 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.26 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.19 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.22 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.29 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.25 | -151.0% |
| Q3 FY2023 | Sep 30, 2023 | -$0.20 | -164.5% |
| Q2 FY2023 | Jun 30, 2023 | -$0.23 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.53 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.49 | – |
| Q2 FY2022 | Jun 30, 2022 | $0.31 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?